CA2960044A1 - Nouveaux sels de 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofurane-2-carboxamide, formes cristallines apparentees, procede pour leur preparation et compositions pharmaceutiques les contenant - Google Patents

Nouveaux sels de 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofurane-2-carboxamide, formes cristallines apparentees, procede pour leur preparation et compositions pharmaceutiques les contenant Download PDF

Info

Publication number
CA2960044A1
CA2960044A1 CA2960044A CA2960044A CA2960044A1 CA 2960044 A1 CA2960044 A1 CA 2960044A1 CA 2960044 A CA2960044 A CA 2960044A CA 2960044 A CA2960044 A CA 2960044A CA 2960044 A1 CA2960044 A1 CA 2960044A1
Authority
CA
Canada
Prior art keywords
expressed
crystalline form
theta
powder
degrees
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2960044A
Other languages
English (en)
Inventor
Marina Gaillard
Philippe Letellier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacyclics LLC
Original Assignee
Pharmacyclics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR1458215A external-priority patent/FR3025196B1/fr
Priority claimed from FR1458224A external-priority patent/FR3025197B1/fr
Application filed by Pharmacyclics LLC filed Critical Pharmacyclics LLC
Publication of CA2960044A1 publication Critical patent/CA2960044A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
    • G01N23/20—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01V—GEOPHYSICS; GRAVITATIONAL MEASUREMENTS; DETECTING MASSES OR OBJECTS; TAGS
    • G01V3/00—Electric or magnetic prospecting or detecting; Measuring magnetic field characteristics of the earth, e.g. declination, deviation
    • G01V3/14—Electric or magnetic prospecting or detecting; Measuring magnetic field characteristics of the earth, e.g. declination, deviation operating with electron or nuclear magnetic resonance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

L'invention concerne des sels de 3-[(diméthylamino)méthyl]-N-{2-[4-(hydroxycarbamoyl)phénoxyl]éthyl}-1-benzofurane-2-carboxamide, en particulier celui de formule (I) : (formule (I)) dans laquelle HA représente l'acide naphtalène-1,5-disulfonique, l'acide naphtalène-2-sulfonique, l'acide oxalique, l'acide benzènesulfonique ou l'acide sulfurique, ou leurs hydrates et leurs formes cristallines, caractérisés par le diagramme de diffraction des rayons X sur poudre et le spectre RMN 13C à l'état solide CP/MAS. L'invention concerne également des compositions, des procédés d'utilisation ou de préparation de celles-ci.
CA2960044A 2014-09-03 2015-09-03 Nouveaux sels de 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofurane-2-carboxamide, formes cristallines apparentees, procede pour leur preparation et compositions pharmaceutiques les contenant Abandoned CA2960044A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR1458215 2014-09-03
FR1458215A FR3025196B1 (fr) 2014-09-03 2014-09-03 Nouveaux sels de 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofurane-2-carboxamide, formes cristallines associees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR1458224A FR3025197B1 (fr) 2014-09-03 2014-09-03 Nouveau sel de 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofurane-2-carboxamide, formes cristallines associees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR1458224 2014-09-03
PCT/US2015/048243 WO2016036910A1 (fr) 2014-09-03 2015-09-03 Nouveaux sels de 3-[(diméthylamino)méthyl]-n-{2-[4-(hydroxycarbamoyl)phénoxy]éthyl}-1-benzofurane-2-carboxamide, formes cristallines apparentées, procédé pour leur préparation et compositions pharmaceutiques les contenant

Publications (1)

Publication Number Publication Date
CA2960044A1 true CA2960044A1 (fr) 2016-03-10

Family

ID=54186276

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2960044A Abandoned CA2960044A1 (fr) 2014-09-03 2015-09-03 Nouveaux sels de 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofurane-2-carboxamide, formes cristallines apparentees, procede pour leur preparation et compositions pharmaceutiques les contenant

Country Status (10)

Country Link
US (2) US20170266151A1 (fr)
EP (1) EP3189040B1 (fr)
JP (1) JP2017530106A (fr)
KR (1) KR20170043648A (fr)
CN (1) CN107001307A (fr)
AU (1) AU2015311905B2 (fr)
CA (1) CA2960044A1 (fr)
MX (1) MX2017002858A (fr)
SG (2) SG10201901916WA (fr)
WO (1) WO2016036910A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170043648A (ko) 2014-09-03 2017-04-21 파마싸이클릭스 엘엘씨 3-[(디메틸아미노)메틸]-n-｛2-[4-(히드록시카르바모일)페녹시]에틸｝-1-벤조푸란-2-카르복사미드의 신규 염, 관련 결정형, 이의 제조 방법 및 이를 함유하는 약학 조성물
WO2022261401A1 (fr) * 2021-06-10 2022-12-15 Teva Pharmaceuticals International Gmbh Formes à l'état solide d'abexinostat et leur procédé de préparation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3038004A (en) 1958-04-18 1962-06-05 Burroughs Wellcome Co Quaternary ammonium compounds
GB0020721D0 (en) 2000-08-22 2000-10-11 Merck Sharp & Dohme Therapeutic agents
SI1611088T1 (sl) * 2003-04-07 2009-12-31 Pharmacyclics Inc Hidroksamati kot terapevtska sredstva
BRPI0418200A (pt) 2003-12-25 2007-04-17 Eisai Co Ltd forma cristalina do sal de 4-(3-cloro-4-(ciclopropilaminocarbonila) aminofenóxi)-7-metóxi-6-quinolinacarboxamida ou o solvato do sal e um processo para a sua preparação
US8702670B2 (en) 2004-06-30 2014-04-22 Mcneil-Ppc, Inc. Intravaginal device with controlled expansion
US20090270497A1 (en) * 2008-04-24 2009-10-29 Pharmacyclics, Inc. Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors
US8603521B2 (en) * 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
AU2010299483B2 (en) 2009-09-24 2014-08-28 Sun Pharmaceutical Industries Limited Process for the preparation of sorafenib tosylate
EP2683371B1 (fr) * 2011-03-09 2020-10-21 Cereno Scientific AB Composés et procédés d'amélioration d'une fibrinolyse endogène dysfonctionnelle à l'aide d'inhibiteurs d'histone désacétylase
FR2977492B1 (fr) 2011-07-04 2013-07-05 Servier Lab Nouvelle association entre le n-hydroxy-4-{2-[3-(n,n-dimethylaminomethyl) benzofuran-2-ylcarbonylamino]ethoxy}benzamide et le folfox
WO2013039956A2 (fr) 2011-09-14 2013-03-21 The Trustees Of Columbia University In The City Of New York Compositions et méthodes de traitement de troubles de l'humeur
CN102531964B (zh) * 2011-10-10 2014-06-11 华东理工大学 具有抗肿瘤作用的二元羧酸衍生物及制备方法
FR3002733B1 (fr) 2013-03-04 2015-08-14 Servier Lab Nouveau sel de l'abexinostat, forme cristalline associee,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
KR20170043648A (ko) 2014-09-03 2017-04-21 파마싸이클릭스 엘엘씨 3-[(디메틸아미노)메틸]-n-｛2-[4-(히드록시카르바모일)페녹시]에틸｝-1-벤조푸란-2-카르복사미드의 신규 염, 관련 결정형, 이의 제조 방법 및 이를 함유하는 약학 조성물

Also Published As

Publication number Publication date
EP3189040B1 (fr) 2020-07-29
MX2017002858A (es) 2017-10-24
AU2015311905B2 (en) 2020-03-05
US20200069637A1 (en) 2020-03-05
SG10201901916WA (en) 2019-04-29
US20170266151A1 (en) 2017-09-21
EP3189040A1 (fr) 2017-07-12
KR20170043648A (ko) 2017-04-21
SG11201701674RA (en) 2017-04-27
CN107001307A (zh) 2017-08-01
JP2017530106A (ja) 2017-10-12
WO2016036910A1 (fr) 2016-03-10
US10898461B2 (en) 2021-01-26
AU2015311905A1 (en) 2017-03-23

Similar Documents

Publication Publication Date Title
ES2935349T3 (es) Compuestos de 5-metil-1,3,4-oxadiazol-2-ilo
ES2952770T3 (es) Formas de estado sólido de apalutamida
RU2639149C2 (ru) Кристаллический полиморф 4-[5-(пиридин-4-ил)-1н-1,2,4-триазол-3-ил]-пиридин-2-карбонитрила и способ его получения
KR20170082450A (ko) 항감염성 화합물
JPS59167587A (ja) オメプラゾ−ル化合物
FR2928645A1 (fr) Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation
WO2021136463A1 (fr) Dérivé purine et son utilisation médicale
CA2938187C (fr) Formes solides de 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions les comprenant et procedes pour les utiliser
WO2015120800A1 (fr) Composé hétérocyclique d'azote, procédé de préparation et utilisation de celui-ci
AU2021207143B2 (en) Optically pure oxaspiro-substituted pyrrolopyrazole derivative, preparation method therefor and pharmaceutical use thereof
EP2382215B1 (fr) Dérivés de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur préparation et leur application en thérapeutique
CA3064484A1 (fr) Composes inhibiteurs des canaux ioniques pour le traitement du cancer
AU2019319835A1 (en) Indole and azaindole inhibitors of PAD enzymes
CA3168211A1 (fr) Derive de pyrrolopyridine et son utilisation dans la prevention et le traitement d'une maladie liee a la proteine kinase
BR112014003146B1 (pt) 3,4-dihidro-1h-[1,8]naftiridinonas substituídas com homopiperidinila antibacterianas, composição farmacêutica compreendendo os referidos composto e processos para preparação destes
SG191924A1 (en) Solid forms of gyrase inhibitor (r)-1-ethyl-3-[5-[2-{1-hydroxy-1-methyl-ethyl}pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl}-1h-benzimidazol-2-yl]urea
CA2960044A1 (fr) Nouveaux sels de 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofurane-2-carboxamide, formes cristallines apparentees, procede pour leur preparation et compositions pharmaceutiques les contenant
BR112020021664A2 (pt) composto de formamida, método de preparação do mesmo e aplicação do mesmo
TW202122372A (zh) 2-胺基喹唑啉酮衍生物
CN114315798A (zh) 喹唑啉类化合物及其药物组合物
CA3135161A1 (fr) Derives d'imidazoquinoline amine, composition pharmaceutique, utilisation de ceux-ci
CN110167554B (zh) 一种具有抗癌作用的化合物及其制备方法和应用
AU2013320407A1 (en) Macrolide derivatives, preparation thereof and therapeutic use thereof
US2709700A (en) Penicillin salt of bis-(alpha-phenethyl)-ethylene diamine
CN110167917B (zh) 一种具有抗癌作用的化合物及其制备方法和应用

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20211124

FZDE Discontinued

Effective date: 20211124